Browse

Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer

DC Field Value Language
dc.contributor.authorPark, Joon Oh-
dc.contributor.authorKim, Sang-We-
dc.contributor.authorAhn, Jin Seok-
dc.contributor.authorSuh, Cheolwon-
dc.contributor.authorLee, Jung Shin-
dc.contributor.authorJang, Joung Soon-
dc.contributor.authorCho, Eun Kyung-
dc.contributor.authorYang, Sung Hyun-
dc.contributor.authorChoi, Jin-Hyuk-
dc.contributor.authorHeo, Dae Seog-
dc.contributor.authorPark, Suk Young-
dc.contributor.authorShin, Sang Won-
dc.contributor.authorAhn, Myung Ju-
dc.contributor.authorLee, Jong Seok-
dc.contributor.authorYun, Young Ho-
dc.contributor.authorLee, Jae-Won-
dc.contributor.authorPark, Keunchil-
dc.date.accessioned2010-01-12T06:47:34Z-
dc.date.available2010-01-12T06:47:34Z-
dc.date.issued2007-11-21-
dc.identifier.citationJ Clin Oncol. 2007 Nov 20;25(33):5233-9.en
dc.identifier.issn1527-7755 (Electronic)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18024869-
dc.identifier.urihttps://hdl.handle.net/10371/29739-
dc.description.abstractPURPOSE: This trial was conducted to determine the optimal duration of chemotherapy in Korean patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with stages IIIB to IV NSCLC who had not progressed after two cycles of chemotherapy were randomly assigned to receive either four (arm A) or two (arm B) more cycles of third-generation, platinum-doublet treatment. RESULTS: Of the 452 enrolled patients, 314 were randomly assigned to the groups. One-year survival rates were 59.0% in arm A and 62.4% in arm B, and the difference of 3.4% (95% CI, -8.0 to 4.8) met the predefined criteria for noninferiority. The median time to progression (TTP), however, was 6.2 months (95% CI, 5.7 to 6.7 months) in arm A and 4.6 months (95% CI, 4.4 to 4.8 months) in arm B, the difference of which is statistically significant (P = .001). The frequencies of hematologic and nonhematologic toxicities were similar in the two arms. CONCLUSION: This study confirms the noninferiority of overall survival with four cycles compared with six cycles of chemotherapy for the first-line treatment of advanced NSCLC and supports the current American Society of Clinical Oncology guidelines. Notably, patients receiving six cycles of chemotherapy compared with four cycles showed a favorable TTP, suggesting that further investigation of the new strategies of maintenance therapy with less toxic agents after three to four cycles of induction chemotherapy might be warranted to improve survival, with consideration of both ethnicity and pharmacogenomic signatures.en
dc.language.isoen-
dc.publisherAmerican Society of Clinical Oncologyen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*administration &en
dc.subjectdosage/adverse effectsen
dc.subjectCarcinoma, Non-Small-Cell Lung/*drug therapy/mortality/psychologyen
dc.subjectCisplatin/administration & dosageen
dc.subjectDisease Progressionen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectLung Neoplasms/*drug therapy/mortality/psychologyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectQuality of Lifeen
dc.subjectTime Factorsen
dc.titlePhase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung canceren
dc.typeArticleen
dc.contributor.AlternativeAuthor박준오-
dc.contributor.AlternativeAuthor김상위-
dc.contributor.AlternativeAuthor안진석-
dc.contributor.AlternativeAuthor서철원-
dc.contributor.AlternativeAuthor이정신-
dc.contributor.AlternativeAuthor장정순-
dc.contributor.AlternativeAuthor조은경-
dc.contributor.AlternativeAuthor양성현-
dc.contributor.AlternativeAuthor최진혁-
dc.contributor.AlternativeAuthor허대석-
dc.contributor.AlternativeAuthor박석영-
dc.contributor.AlternativeAuthor신상원-
dc.contributor.AlternativeAuthor안명주-
dc.contributor.AlternativeAuthor이종석-
dc.contributor.AlternativeAuthor윤영호-
dc.contributor.AlternativeAuthor이재원-
dc.contributor.AlternativeAuthor박근칠-
dc.identifier.doi10.1200/JCO.2007.10.8134-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Program in Cancer Biology (협동과정-종양생물학전공)Journal Papers (저널논문_협동과정-종양생물학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse